Takeda sets sights on first-line lung cancer market with new Alunbrig dataPfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a Share XTakeda sets sights on first-line lung cancer market with new Alunbrig datahttps://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/
